Ultragenyx Pharmaceutical Inc. Stock price

Equities

RARE

US90400D1081

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
46.69 USD -0.28% Intraday chart for Ultragenyx Pharmaceutical Inc. +0.09% -2.36%
Sales 2024 * 515M Sales 2025 * 633M Capitalization 3.84B
Net income 2024 * -532M Net income 2025 * -453M EV / Sales 2024 * 6.82 x
Net cash position 2024 * 334M Net cash position 2025 * 298M EV / Sales 2025 * 5.6 x
P/E ratio 2024 *
-7.24 x
P/E ratio 2025 *
-9.06 x
Employees 1,276
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.88%
More Fundamentals * Assessed data
Dynamic Chart
JPMorgan Adjusts Price Target on Ultragenyx Pharmaceutical to $92 From $88, Maintains Overweight Rating MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 04:20 PM
Ultragenyx Pharmaceutical Insider Sold Shares Worth $574,644, According to a Recent SEC Filing MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:10 AM
Canaccord Genuity Adjusts Ultragenyx Pharmaceutical's Price Target to $111 From $110, Keeps Buy Rating MT
Sector Update: Health Care Stocks Gain Pre-Bell Friday MT
Wedbush Lifts Ultragenyx Pharmaceutical's PT to $48 From $47, Notes Fuller Catalyst Lineup for 2024; Keeps Neutral Rating MT
Ultragenyx Pharmaceutical Q4 Loss Narrows, Revenue Rises; 2024 Revenue Guidance Set MT
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 15, 2024
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q4 Revenue $127.4M MT
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024 CI
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Ultragenyx Says UX111 Treatment Results Correlate With Improved Cognitive Function MT
Ultragenyx Pharmaceutical Inc. Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) CI
More news
1 day-0.28%
1 week+0.09%
Current month-9.73%
1 month-11.49%
3 months-3.27%
6 months+32.76%
Current year-2.36%
More quotes
1 week
45.01
Extreme 45.01
47.16
1 month
45.01
Extreme 45.01
54.56
Current year
41.87
Extreme 41.87
54.56
1 year
31.52
Extreme 31.52
54.98
3 years
31.52
Extreme 31.52
120.00
5 years
31.52
Extreme 31.52
179.65
10 years
31.52
Extreme 31.52
179.65
More quotes
Managers TitleAgeSince
Founder 63 10-04-21
Director of Finance/CFO 47 23-10-15
Chief Tech/Sci/R&D Officer - 17-10-31
Members of the board TitleAgeSince
Director/Board Member 61 17-04-05
Founder 63 10-04-21
Chairman 66 15-04-07
More insiders
Date Price Change Volume
24-03-28 46.69 -0.28% 543,698
24-03-27 46.82 +2.99% 551,352
24-03-26 45.46 +0.09% 362,335
24-03-25 45.42 -0.94% 442,715
24-03-22 45.85 -1.71% 403,665

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
46.69 USD
Average target price
90.05 USD
Spread / Average Target
+92.87%
Consensus
  1. Stock
  2. Equities
  3. Stock Ultragenyx Pharmaceutical Inc. - Nasdaq